Recombinant Mouse Anti-N. meningitidis LOS Antibody (LPT3-1) (CAT#: PABL-283)

Figure 1 LPT3-1 against LPS from L4 (89I), L2 (35E), and L3 (MC58) N. meningitidis strains.

Gidney, M. A. J., Plested, J. S., Lacelle, S., Coull, P. A., Wright, J. C., Makepeace, K.,... & Richards, J. C. (2004). Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis.Infection and immunity, 72(1), 559-569.

Figure 2 IF of live N. meningitidis strains on monolayers of 16HBE140 cells probed with inner core LPS MAbs, either MAbs L2-16 (a, c, e, and g) or LPT3-1 (i and k) or L3B5 (m and o) and detected using anti-mouse IgG-FITC (green), followed by direct staining using a MAb, L4A3-RRX conjugate (red), respectively (b, d, f, h, j, l, n, and p).

Consecutive pairs of letters—e.g., a and b, c and d, and so on—indicate the same field of view observed for green or red fluorescence. L4A3 recognizes a common outer membrane component conserved in all N. meningitidis strains tested. N. meningitidis strains were as follows: 35E (L2) wild type (a and b), 89I (L4) wild-type (c and d), 35E (L2) galE mutant (e and f), 89I (L4) galE mutant (g and h), MC58 (L3) lpt3 (i and j), MC58 (L3) lpt3 galE mutant (k and l), MC58 (L3) galE (m and n), and MC58 (L3) wild type (o and p).

Gidney, M. A. J., Plested, J. S., Lacelle, S., Coull, P. A., Wright, J. C., Makepeace, K.,... & Richards, J. C. (2004). Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis.Infection and immunity, 72(1), 559-569.

Figure 3 Functional assays using MAbs L2-16 and LPT3-1.

(a) OPA with ethanol-fixed N. meningitidis showing opsonic activity (percent phagocytosis) of L2-16 against 35E (L2) wild type, 35E (L2) galE, and 89I (L4) galE, but not against 89I (L4) wild type. Complement-only controls for L2 (35E), L2 (35E) galE, L4 (89I), and L4 (89I) galE mutants were 3.2, 4.5, 3.4, and 12.2%, respectively. (b) OPA with ethanol-fixed N. meningitidis showing opsonic activity (percent phagocytosis) of LPT3-1 against MC58 lpt3 and MC58 lpt3 galE but not against MC58 galE and MC58 wild type. Complement-only controls for MC58 galE, MC58 lpt3, MC58 lpt3 galE, and MC58 were 16.2, 17.8, 20.3, and 14.6%, respectively. (c) SB assay using N. meningitidis, LPT3-1 and a fixed amount of human complement (see Materials and Methods) showing a dose-response effect on bactericidal activity of LPT3-1 against MC58 lpt3 galE but not against MC58, MC58 lpt3, and MC58 galE. (d) Passive protection studies with L2-16 using a 5-day-old infant rat model (see Materials and Methods): showing the geometric mean bacteremia (log10 CFU/ml) in blood samples taken 18 h after simultaneous treatment with L2-16 (20 g/rat) and challenge with N. meningitidis strains 35E (L2), 35E (L2) galE, 89I (L4), or 89I (L4) galE. Positive control MAbs include anticapsular serogroup C mouse MAb (NIBSC) (undiluted), anti-porin P1.1 mouse MAb (NIBSC) (1:1,000 dilution in PBS-BSA), and human serum (individual with high-titer anticapsular C antibody; equivalent, 0.2 g/rat). Negative controls were given PBS-BSA. (e) Passive protection studies with LPT3-1 using 5-day-old infant rat model (see Materials and Methods) showing geometric mean bacteremia (log10 CFU/ml) in blood samples taken 18 h after simultaneous treatment with LPT3-1 (20 g/rat) and challenge with N. meningitidis strain 8047 or 8047 lpt3. Positive controls included L3B5 (20 g/rat) and anti-porin P1.2 (NIBSC) (1:1,000 dilution in PBS-BSA). Negative controls were given PBS-BSA.

Gidney, M. A. J., Plested, J. S., Lacelle, S., Coull, P. A., Wright, J. C., Makepeace, K.,... & Richards, J. C. (2004). Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis.Infection and immunity, 72(1), 559-569.